REFERENCES
- Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER. Oxidative stress in hemo-dialysis. Q J Med 1994; 87: 679–83.
- Maggie E, Bellazzi R, Falaschi F, Frattoni A, Perani G,
- Jacob RA, Burn i BJ. Oxidative damage and defense. Am J Clin Nutr 1996; 63: 985S–990S.
- Malinow MR. Adverse effects of the treatment for hyperlipidemia. Cardiol Clin 1986; 4: 95–103.
- Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 55–60.
- Williams GM, Perrone C. Mechanism-based risk assessment of peroxisome proliferating rodent hepato-carcinogens. Ann NY Acad Sci 1996; 804: 554–72.]
- Sum CF, Tan CE, Chew LS. Management of hyperli-pidemia. Singapore Med J 1995; 36: 410–16.
- Westhuvzen J, Adams CE, Fleming SJ. Evidence for oxidative stress during in vitro dialysis. Nephron 1995; 70: 49–54.
- Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem 1995; 41: 1135–8.
- Jha P. Flather M, Lonn E, Farkouh H, Yusuf S. The antioxidant vitamins and cardiovascular diseases. A critical review of epidemiologic and clinical trial data. Ann Intern Med 1995; 123: 860–72.
- Peuchant E, Carbonneau MA, Dubourg L, Thomas MJ, Perromat A, Vallot C, Clerc M. Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamin A, E, and iron status. Free Radic Biol Med 1994; 16: 339–46.
- Jendrvczko A, Grzesxczak W, Goren/ea E. Lipid peroxides and vitamin E in plasma and plasma lipoproteins in blood of patients with chronic hemodia-lysis. Pol Arch Med Wewn 1994; 92: 123–8.
- Yeksan M, Turk S, Polat M, Cigli A, Erdogan Y. Effects of 1.25 (OH)2D3 treatment on lipid levels in uremic hemodialysis patients. Int J Artif Organs 1992; 15: 704–7.
- Lind L, Lithel H, Wengle B, Werge U, Ljunghall S. A pilot study of metabolic effects of intravenously given alpha-calcidol in patients with chronic renal failure. Scand J Urol Nephrol 1988; 22: 219–22.
- Coffery MD, Cole RA, Colles SM, Chisoim GM. In vitro cell injury by oxidized low density lipoprotein involves lipid hydroperoxide-induced formation of alkoxyl, lipid, and peroxyl radicals. J Clin Invest 1995; 96: 1866–73.
- Swain R, Kaplan B. Vitamins as therapy in the 1990s. J Am Board Fam Prac 1995; 8: 206–16.
- Galle J, Wanner C. Oxidative stress and vascular injury relevant for atherogenesis in uremic patients? Nephrol Dial Transplant 1997; 12: 2480–3.
- Gilmour ER, Hartley GH, Goodship THJ. Trace elements and vitamins in renal disease. In: Mitch WE, Klahr S, editors. Nutrition and the kidney. Boston: Little Brown, 1993: 114–31.
- Kritchevsky SB, Shimakawa T, Tell GS, Dennis R, Carpenter M, Fekfeldt JH, et al. Dietary antioxidant and carotid wall thickness. The ARIC Study. Circulation 1995; 92: 2142–50.
- Hodis 11N, Mack WJ, LaBaree L, Cashin-Hemphill L, Sevanian A, Johnson R, Azen SP. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995; 273: 1849–54.
- Mancini M, Parfitt VJ, Rubba P. Antioxidant in the Mediterranean diet. Can J Cardiol 1995; 11 (Suppl G): 105G–9G.
- Maclin U. Critical assessment of the epidemiological data concerning the impact of the antioxidant nutrients on cancer and cardiovascular disease. Crit Rev Food Sci Nutr 1995; 35: 41–50.
- Boeshoten EW, Schriever J, Krediet RT, Arisz L. Vitamin deficiencies in CAPD patients. Peril Dial Bull 1984; 4 (Suppl): S7.
- Nishizawa Y, Shoji T, Kawagishi T, Morn i H. Athero-sclerosis in uremia: possible roles of hyperparathyroid-ism and intermediate density lipoprotein accumulation. Kidney Int 1997; 52 (Suppl 62): S90—S2.
- Cohen JJ, Harrington JT, Cassirer JP, Madias NE. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169–83.